Document is current
Any future updates will be listed below
-
Authors
Tucker, Torry A.
Komissarov, Andrey A.
Idell, Steven
-
Funding
Funding for this research was provided by:
NIH (HL14285301, HL154103, HL14285301)
- License Information
-
More Information
Article History
Received: 26 November 2024
Accepted: 9 March 2025
First Online: 18 March 2025
Declarations
:
: Not applicable.
: Not applicable.
: Drs. Tucker and Komissarov declare no COI related to this work and Dr. Idell has a COI Management Plans from the University of Texas at Tyler. Dr. Idell has equity in Aileron Therapeutics Inc., which is commercializing single chain urokinase for pleural loculation and failed drainage in empyema among other products. He founded Lung Therapeutics, Inc which was acquired by Aileron, now called Rein; a publicly traded company. The authors declare no competing interests.
